Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million

Reuters04-02 18:23

Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million

Clover issued a supplemental announcement amending its March 22, 2026 disclosure on a settlement with Gavi by detailing deferred-payment and contingent-payment terms.
Semi-annual deferred payments were clarified as capped at USD 22 million, with each installment set at higher of USD 1.5 million or 3% of consolidated cash and bank balances at mid-year or year-end.
Contingent payments were specified as capped at USD 36 million, including quarterly payments of 8.5% of net revenues received.
Additional contingent payments were defined as 5% of equity financing proceeds up to USD 50 million, rising to 7% above that threshold, over a 12-year term.
Maximum future payments excluding initial USD 7 million were put at USD 34.8 million to USD 58 million, replacing exposure to a USD 224 million repayment claim.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260402-12095075), on April 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624570474?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624570474","market":"us","top_or_hot":-1,"title":"Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clover issued a supplemental announcement amending its March 22, 2026 disclosure on a settlement with Gavi by detailing deferred-payment and contingent-payment terms.\n        </li>\n<li>\n          Semi-annual deferred payments were clarified as capped at USD 22 million, with each installment set at higher of USD 1.5 million or 3% of consolidated cash and bank balances at mid-year or year-end.\n        </li>\n<li>\n          Contingent payments were specified as capped at USD 36 million, including quarterly payments of 8.5% of net revenues received.\n        </li>\n<li>\n          Additional contingent payments were defined as 5% of equity financing proceeds up to USD 50 million, rising to 7% above that threshold, over a 12-year term.\n        </li>\n<li>\n          Maximum future payments excluding initial USD 7 million were put at USD 34.8 million to USD 58 million, replacing exposure to a USD 224 million repayment claim.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260402-12095075), on April 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Bio clarifies Gavi settlement terms, caps future payments at US$58 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-02 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clover issued a supplemental announcement amending its March 22, 2026 disclosure on a settlement with Gavi by detailing deferred-payment and contingent-payment terms.\n        </li>\n<li>\n          Semi-annual deferred payments were clarified as capped at USD 22 million, with each installment set at higher of USD 1.5 million or 3% of consolidated cash and bank balances at mid-year or year-end.\n        </li>\n<li>\n          Contingent payments were specified as capped at USD 36 million, including quarterly payments of 8.5% of net revenues received.\n        </li>\n<li>\n          Additional contingent payments were defined as 5% of equity financing proceeds up to USD 50 million, rising to 7% above that threshold, over a 12-year term.\n        </li>\n<li>\n          Maximum future payments excluding initial USD 7 million were put at USD 34.8 million to USD 58 million, replacing exposure to a USD 224 million repayment claim.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260402-12095075), on April 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL2ykNw5:1","article_id":"2624570474","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624570474","pubTimestamp":1775125401,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clover issued a supplemental announcement amending its March 22, 2026 disclosure on a settlement with Gavi by detailing deferred-payment and contingent-payment terms.Semi-annual deferred payments were clarified as capped at USD 22 million, with each installment set at higher of USD 1.5 million or 3% of consolidated cash and bank balances at mid-year or year-end.Contingent payments were specified as capped at USD 36 million, including quarterly payments of 8.5% of net revenues received.Additional contingent payments were defined as 5% of equity financing proceeds up to USD 50 million, rising to 7% above that threshold, over a 12-year term.Maximum future payments excluding initial USD 7 million were put at USD 34.8 million to USD 58 million, replacing exposure to a USD 224 million repayment claim.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B","BK1161":"生物科技"},"translate_title":"Clover Bio明确Gavi和解条款未来付款上限为5800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":0.9},"content_text":"Clover Bio clarifies Gavi settlement terms, caps future payments at US$58 million\n    \n\n\n          Clover issued a supplemental announcement amending its March 22, 2026 disclosure on a settlement with Gavi by detailing deferred-payment and contingent-payment terms.\n        \n\n          Semi-annual deferred payments were clarified as capped at USD 22 million, with each installment set at higher of USD 1.5 million or 3% of consolidated cash and bank balances at mid-year or year-end.\n        \n\n          Contingent payments were specified as capped at USD 36 million, including quarterly payments of 8.5% of net revenues received.\n        \n\n          Additional contingent payments were defined as 5% of equity financing proceeds up to USD 50 million, rising to 7% above that threshold, over a 12-year term.\n        \n\n          Maximum future payments excluding initial USD 7 million were put at USD 34.8 million to USD 58 million, replacing exposure to a USD 224 million repayment claim.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260402-12095075), on April 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624570474","isCrawlerRequest":true}